TSUMURA & CO. Logo

TSUMURA & CO.

A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1893, Tsumura & Co. is a leading Japanese pharmaceutical company specializing in Kampo medicine, a traditional Japanese herbal therapy. The company's primary business is the manufacture and sale of prescription and over-the-counter (OTC) Kampo formulations, which are derived from natural substances. Its product portfolio also includes other medications and consumer items such as herbal bath salts. Tsumura manages an integrated value chain, from the procurement of raw medicinal herbs to the production of finished goods. The company is guided by a philosophy of achieving “Cho-WA” (harmony) between mind and body, blending tradition with scientific innovation to contribute to individual and societal well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 08:16
Interim Report
確認書
Japanese 8.9 KB
2025-11-11 08:14
Interim Report
半期報告書-第90期(2025/04/01-2026/03/31)
Japanese 267.3 KB
2025-09-10 07:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-08-05 07:44
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2025-07-08 07:37
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-07-01 09:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第89期(2024/04/01-2025/03/31)
Japanese 25.7 KB
2025-06-24 06:21
Annual Report
有価証券報告書-第89期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2025-06-24 06:21
Registration Form
確認書
Japanese 8.9 KB
2025-06-11 06:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-05-12 07:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.0 KB
2025-04-07 07:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-03-10 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-03-03 08:27
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.2 KB
2025-02-20 07:30
Share Issue/Capital Change
臨時報告書
Japanese 27.8 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.